Ibio Inc (IBIO) : Arcus Capital Partners has sold out all of its stake in Ibio Inc during the most recent quarter, according to the disclosure filed by the company on Aug 2, 2016 with the SEC. The investment management company has sold out 1,004,591 shares of Ibio Inc which is valued at $693,168.
Other Hedge Funds, Including , Creative Planning added IBIO to its portfolio by purchasing 3,130 company shares during the most recent quarter which is valued at $2,056.
Ibio Inc (IBIO) witnessed a volatile trading activity on Monday , and eventually ended flat at 0.00% or 0 points without letting the bulls or bears take much advantage. The trading began at $0.69 and reached the intraday high at $0.69. The bulls started the profit booking and pushed the shares to intraday low of $0.66. The trading session was marked by a volume range of 46,517 shares exchanging hands. The 52-week high of the shares is $0.95 and the 52-week low is $0.45. The market cap of the company stands at $61 M and there are 8,91,09,410 shares in public circulation.
iBio Inc. is a biotechnology company. The Company focuses on commercializing its platform technologies iBioLaunch and iBioModulator and developing select product candidates based upon these platforms. iBioLaunch is a transformative platform technology for the development and production of biologics using transient gene expression in hydroponically grown unmodified green plants. iBioModulator is a technology platform that is designed to improve the potency and duration of effect of both prophylactic and therapeutic vaccines produced with any recombinant expression technology including iBioLaunch. The iBio pipeline includes products against fibrotic diseases vaccines enzyme replacements monoclonal antibodies and recombinant versions of marketed products that are derived from human blood plasma. The Company developed its iBioModulator technology based on the use of a modified form of the cellulose degrading enzyme lichenase (LicKM) from Clostridium thermocellum.